Recursion Trial Update with CEO Chris Gibson, Ph.D.

📅 Mar 14, 2025 Alliance to Cure Cavernous Malformation 40 MIN 544 VIEWS 10 SEGMENTS · 2 SPEAKERS

Join Chris Gibson, Ph.D., CEO of Recursion, for an update on REC-994, the first drug trial designed specifically for CCM patients. He’ll share the latest trial progress, what it means for the community, and what comes next. Tune in to learn more about this important step toward a potential treatment. Please note: The Q&A session was not recorded.

Questions asked in this interview

0:32Are you in Salt Lake right now?

Connie Lee 0:06 ↗

Okay, hello everybody. We're going to wait just a few minutes and allow folks to start rolling in. We can watch the count go up as you all are able to get into the webinar. And we're really looking forward to tonight's webinar. This is a treat for us to have Chris, and I am anxiously awaiting what he's going to be sharing with us.

Chris Gibson 0:29 ↗

Thanks, Connie. I'm excited to be here. I can't wait to speak to this group.

Connie Lee 0:32 ↗

You're welcome. Are you in Salt Lake right now?

Chris Gibson 0:35 ↗

I am in Salt Lake. I'm in an office that I spent a lot of time in, surrounded by whiteboard walls, where we try to ideate all kinds of interesting science.

Connie Lee 0:46 ↗

And how's the weather?

5 more exchanges in this transcript

Cite this transcript

APA, MLA, BibTeX

APA

Gibson, C. (2025, March 14). Recursion Trial Update with CEO Chris Gibson, Ph.D. [Interview transcript]. Alliance to Cure Cavernous Malformation. CEOInterviews.AI. https://ceointerviews.ai/interview/3011892/

MLA

Chris Gibson. "Recursion Trial Update with CEO Chris Gibson, Ph.D.." Alliance to Cure Cavernous Malformation, 14 Mar. 2025. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3011892/.

BibTeX

@misc{gibson2025_3011892,
  author       = {Chris Gibson},
  title        = {Recursion Trial Update with CEO Chris Gibson, Ph.D.},
  howpublished = {Interview transcript, Alliance to Cure Cavernous Malformation. CEOInterviews.AI},
  year         = {2025},
  month        = {mar},
  url          = {https://ceointerviews.ai/interview/3011892/},
  note         = {Speaker-attributed transcript with timestamps}
}

▶

Key Quotes (2)

“We're the first company that's ever gone to the FDA to do a phase two trial. So there was not a clear regulatory framework for us to work in. There wasn't somebody the FDA who could say, hey, you know another company just ran a trial here, and we are. We previously negotiated with them. What the best things to measure are, you should replicate that. We actually got to work with our partners at the”

▶ 18:19 POLICY

“What we see in the high dose is actually there's 1-234-567-8910, patients out of the 21 so nearly half of the patients who saw their their lesion get smaller over the course of 12 months. And you can compare that here with 12345, so roughly 25% of the patients in the placebo group, so basically twice as many patients in the high dose treatment group saw their lesion decrease in size. Now, what was”

▶ 27:31 POLICY

More interviews with Chris Gibson

A Hypothesis-Agnostic Approach to Accelerating Drug Discovery - Dr. Chris Gibson, Co-Founder and ...Aug 12, 2026 · Osmosis from Elsevier · 31 min
From PhD Research to Multi-Billion-Dollar Biotech Startup: Chris Gibson on Recursion’s OriginJun 01, 2026 · University of Utah Technology Licensing Office · 32 min
TechBio Talks Episode 2: Broad Institute's Anne Carpenter with Host Chris GibsonOct 01, 2025 · Recursion · 23 min
Ep114: Chris Gibson on Industrializing Drug DiscoveryJun 11, 2025 · The Long Run with Luke Timmerman · 66 min
AI & Machine Learning | Dr. Chris GibsonMay 27, 2025 · Good Medicine Podcast · 42 min

All Chris Gibson transcripts →

About Chris Gibson

Chris Gibson, co-founder and former CEO of Recursion, discussed the company’s approach to drug discovery in an August 2026 podcast appearance. He described Recursion’s laboratory capabilities, stating that it can conduct up to 2.2 million experiments per week using automated systems. Gibson noted that the company has knocked out every gene in the human genome across multiple cell types and uses imaging and other high-dimensional data to train neural networks aimed at understanding gene and protein relationships. He also mentioned partnerships with Roche Genentech in neuroscience and oncology, and with Bayer in fibrosis, describing these as collaborations to uncover new targets and co-develop treatments before partners take them into clinical trials. Gibson reflected on Recursion’s history, including its founding from his MD-PhD work at the University of Utah, and discussed the company’s strategy of building its own pipeline while partnering on large, expensive therapeutic areas such as Parkinson’s, Alzheimer’s, and ALS. He attributed the acceleration of drug testing to converging advances in genetics, computing, artificial intelligence, and mRNA technology. Gibson also offered advice to academics considering industry roles, saying that industry can be fulfilling and that academic work should not be entirely ruled out.

All Chris Gibson appearances → Alliance to Cure Cavernous Malformation on YouTube →